Culver City, California Saturday, March 1, 2025, 17:00 Hrs [IST] ...

Mustang Bio, Inc. ("Mustang" or the "Company") (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs ...

Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on ...

The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, ...

Clinical trials planned to begin patient enrollment during 2025 to evaluate Gylden’s T cell Priming (TcP) candidates against Dengue (Phase II) ...

Technology Networks spoke to Professor Thomas Rademacher, co-founder, executive director and CEO at Gylden Pharma Limited, to ...